Alex Therapeutics designs and creates CE-certified Digital Therapeutics (DTx) medical products that combine AI with CBT.
At Alex Therapeutics, we develop CE-certified Digital Therapeutics (DTx) products. We are a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artificial Intelligence to provide our patients with highly personalized and effective care. Our first product, Alex Smoke-Free, combines CBT with AI to help the user become smoke-free. 50,000 people on three continents currently use it, and 52% of those who go through the program successfully quit smoking, 7 times more than nicotine replacement medicine. The Alex Platform allows for the easy development of new products and we see incredible potential in future verticals such as obesity, depression, oncology, and more.
Total Funding: $628,422
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: 2018
For AI Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI Startup founders or founders at Alex Therapeutics
Software Engineer
Stockholm, Stockholm
Product Designer
Stockholm, Stockholm
Business Intern
Stockholm, Stockholm
Alex Therapeutics - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups
Alex Therapeutics - Manage Profile
World's Most Promising AI Startups
World's Leading AI Ecosystem of AI Startups, Founders, Investors, and AI Professionals
Get Started